|
CA2277112C
(en)
*
|
1997-01-07 |
2008-08-26 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the reduction of food intake
|
|
WO1999025727A2
(en)
|
1997-11-14 |
1999-05-27 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
US7220721B1
(en)
*
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
|
US7223725B1
(en)
*
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
US20030087820A1
(en)
*
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
|
EP1609478A1
(en)
*
|
1999-01-14 |
2005-12-28 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptide formulations
|
|
US6514500B1
(en)
*
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
|
US6506724B1
(en)
*
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
ES2347137T3
(es)
*
|
2000-10-20 |
2010-10-26 |
Amylin Pharmaceuticals, Inc. |
Tratamiento de miocardio hibernante y cardiomiopatia diabetica con un peptido gpl-1.
|
|
CN1162446C
(zh)
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
|
EP2022505B1
(en)
|
2001-07-31 |
2011-12-14 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
GLP-1, exendin-4, peptide analogs and uses thereof
|
|
ES2327328T3
(es)
*
|
2002-07-04 |
2009-10-28 |
Zealand Pharma A/S |
Glp-1 y procedimientos para el tratamiento de la diabetes.
|
|
WO2004035762A2
(en)
*
|
2002-10-17 |
2004-04-29 |
Alkermes Controlled Therapeutics, Inc. Ii |
Microencapsulation and sustained release of biologically active polypeptides
|
|
BR0315523A
(pt)
*
|
2002-10-22 |
2005-08-30 |
Waratah Pharmaceuticals Inc |
Tratamento de diabetes
|
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
|
US8008255B2
(en)
*
|
2003-05-30 |
2011-08-30 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
|
US20060210614A1
(en)
*
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
US20060074025A1
(en)
*
|
2003-12-26 |
2006-04-06 |
Nastech Pharmaceutical Company Inc. |
Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
|
|
US20080318837A1
(en)
*
|
2003-12-26 |
2008-12-25 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
|
|
US20050143303A1
(en)
*
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
|
BRPI0507189A
(pt)
*
|
2004-01-30 |
2007-06-26 |
Waratah Pharmaceuticals Inc |
uso combinado de um agonista de glp-1 e compostos de gastrina
|
|
EP2335715A3
(en)
*
|
2004-02-11 |
2013-12-18 |
Amylin Pharmaceuticals, LLC |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
|
US8076288B2
(en)
*
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
US7456254B2
(en)
*
|
2004-04-15 |
2008-11-25 |
Alkermes, Inc. |
Polymer-based sustained release device
|
|
US20060110423A1
(en)
*
|
2004-04-15 |
2006-05-25 |
Wright Steven G |
Polymer-based sustained release device
|
|
CN1968700A
(zh)
|
2004-04-15 |
2007-05-23 |
阿尔克姆斯有限公司 |
聚合物基的持续释放装置
|
|
CA2564031A1
(en)
|
2004-04-23 |
2005-11-03 |
Conjuchem Biotechnologies Inc. |
Method for the purification of albumin conjugates
|
|
US20090069226A1
(en)
*
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
|
EP1853627A2
(en)
|
2005-02-11 |
2007-11-14 |
Amylin Pharmaceuticals, Inc. |
Gip analog and hybrid polypeptides with selectable properties
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
AU2006265814B2
(en)
|
2005-06-30 |
2012-05-10 |
Ipsen Pharma S.A.S. |
GLP-1 pharmaceutical compositions
|
|
JP2009504681A
(ja)
*
|
2005-08-11 |
2009-02-05 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
選択可能な特性を有するハイブリッドポリペプチド
|
|
EP1922336B1
(en)
*
|
2005-08-11 |
2012-11-21 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
|
WO2007053946A1
(en)
*
|
2005-11-09 |
2007-05-18 |
Conjuchem Biotechnologies Inc. |
Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
|
|
BRPI0620571A2
(pt)
*
|
2005-12-08 |
2011-11-22 |
Nastech Pharm Co |
formulação farmacêutica aquosa, forma de dosagem de exendina, solução aquosa, uso de uma formulação farmacêutica, e uso de uma formulação farmacêutica aquosa
|
|
US20070269863A1
(en)
*
|
2005-12-22 |
2007-11-22 |
Bridon Dominique P |
Process for the production of preformed conjugates of albumin and a therapeutic agent
|
|
EA200870575A1
(ru)
*
|
2006-05-26 |
2009-08-28 |
Амилин Фармасьютикалз, Инк. |
Композиции и способы лечения застойной сердечной недостаточности
|
|
ES2351527T3
(es)
|
2006-05-30 |
2011-02-07 |
Intarcia Therapeutics, Inc |
Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
|
|
KR101200728B1
(ko)
|
2006-08-09 |
2012-11-13 |
인타르시아 세라퓨틱스 인코포레이티드 |
삼투성 전달 시스템 및 피스톤 조립체
|
|
EP2056673A4
(en)
*
|
2006-08-17 |
2010-06-16 |
Wellstat Therapeutics Corp |
COMBINATION TREATMENT FOR METABOLISM DISEASES
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
RU2413528C2
(ru)
|
2007-01-18 |
2011-03-10 |
Открытое Акционерное Общество "Валента Фармацевтика" |
Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
|
|
AU2008231093A1
(en)
*
|
2007-03-22 |
2008-10-02 |
Alkermes, Inc. |
Coacervation process
|
|
RU2440097C2
(ru)
|
2007-04-23 |
2012-01-20 |
Интарсия Терапьютикс, Инк. |
Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
|
|
EP2164519A2
(en)
*
|
2007-06-08 |
2010-03-24 |
Ascendis Pharma AS |
Long-acting polymeric prodrugs of exendin
|
|
JP2011506442A
(ja)
*
|
2007-12-11 |
2011-03-03 |
コンジュケム バイオテクノロジーズ インコーポレイテッド |
インスリン分泌性ペプチド結合体の製剤
|
|
CA2726861C
(en)
|
2008-02-13 |
2014-05-27 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
WO2009125423A2
(en)
|
2008-04-07 |
2009-10-15 |
National Institute Of Immunology |
Compositions useful for the treatment of diabetes and other chronic disorder
|
|
ES2552646T3
(es)
|
2008-05-21 |
2015-12-01 |
Amylin Pharmaceuticals, Inc. |
Exendinas para disminuir el colesterol y los triglicéridos
|
|
US20120058105A1
(en)
*
|
2008-06-27 |
2012-03-08 |
Martin Kean Chong Ng |
Method of treatment of vascular complications
|
|
EP2216042A1
(en)
|
2009-02-09 |
2010-08-11 |
Ipsen Pharma S.A.S. |
GLP-1 analogues pharmaceutical compositions
|
|
US20120231022A1
(en)
|
2009-05-28 |
2012-09-13 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds for sleep enhancement
|
|
US9265723B2
(en)
|
2009-07-31 |
2016-02-23 |
Sanofi-Aventis Deutschland Gmbh |
Long acting insulin composition
|
|
KR20120089843A
(ko)
|
2009-07-31 |
2012-08-14 |
사노피-아벤티스 도이칠란트 게엠베하 |
인슐린 링커 접합체를 포함한 프로드럭
|
|
HRP20171801T1
(hr)
|
2009-09-28 |
2017-12-29 |
Intarcia Therapeutics, Inc. |
Brzo uspostavljanje i/ili brzo završavanje uglavnom stabilne primjene lijeka
|
|
JP5892940B2
(ja)
|
2009-11-25 |
2016-03-23 |
アリスジェン ソシエテ アノニム |
クラウン化合物及び／又は対イオンと複合体化されたペプチドを含む粘膜送達組成物
|
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
|
NZ603169A
(en)
|
2010-04-27 |
2015-02-27 |
Zealand Pharma As |
Peptide conjugates of glp-1 receptor agonists and gastrin and their use
|
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
|
US9161953B2
(en)
|
2010-12-22 |
2015-10-20 |
Amylin Pharmaceuticals, Llc |
GLP-1 receptor agonists for islet cell transplantation
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
CA2853884A1
(en)
|
2011-11-03 |
2013-05-10 |
Zealand Pharma A/S |
Glp-1 receptor agonist peptide gastrin conjugates
|
|
US20130289241A1
(en)
*
|
2012-04-26 |
2013-10-31 |
Shanghai Ambiopharm, Inc. |
Method for preparing exenatide
|
|
ES2620111T3
(es)
|
2012-07-23 |
2017-06-27 |
Zealand Pharma A/S |
Análogos de glucagón
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
RS57531B1
(sr)
|
2012-12-21 |
2018-10-31 |
Sanofi Sa |
Derivati eksendina-4 kao dualni glp1/gip- ili trigonalni glp1/gip/glukagon agonisti
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
US9896495B2
(en)
|
2013-10-17 |
2018-02-20 |
Zealand Pharma A/S |
Acylated glucagon analogues
|
|
CA2929107C
(en)
|
2013-11-06 |
2023-09-26 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
|
AU2014345569B2
(en)
|
2013-11-06 |
2020-08-13 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
|
WO2015086729A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
EP3080150B1
(en)
|
2013-12-13 |
2018-08-01 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
RU2573933C1
(ru)
|
2014-08-21 |
2016-01-27 |
Дафот Энтерпрайсис Лимитед |
Пептид для лечения сахарного диабета 2-го типа и его осложнений
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
MX381640B
(es)
|
2014-10-29 |
2025-03-04 |
Zealand Pharma As |
Metodos y compuestos agonistas de gip.
|
|
US10415934B2
(en)
*
|
2015-02-27 |
2019-09-17 |
Burris Company, Inc. |
Self-aligning optical sight mount
|
|
ES2763329T3
(es)
|
2015-04-16 |
2020-05-28 |
Zealand Pharma As |
Análogo de glucagón acilado
|
|
CN113598842A
(zh)
|
2015-06-03 |
2021-11-05 |
因塔西亚制药公司 |
植入物放置和移除系统
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
|
|
JP7011830B2
(ja)
|
2015-10-14 |
2022-01-27 |
エックス－サーマ インコーポレイテッド |
氷晶形成を低減するための組成物および方法
|
|
US10294303B2
(en)
|
2015-12-23 |
2019-05-21 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
|
|
RU2760007C2
(ru)
|
2016-05-16 |
2021-11-22 |
Интарсия Терапьютикс, Инк. |
Полипептиды, селективные к рецепторам глюкагона, и способы их применения
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
EP3551202B1
(en)
|
2016-12-06 |
2024-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
|
|
DK3551651T3
(da)
|
2016-12-09 |
2024-05-13 |
Zealand Pharma As |
Acylerede glp-1/glp-2-dobbeltagonister
|
|
WO2018129058A1
(en)
|
2017-01-03 |
2018-07-12 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
|
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
|
KR20200019122A
(ko)
|
2017-06-20 |
2020-02-21 |
암젠 인크 |
Glp-1 작용제와 조합하여 위 저해 펩타이드 수용체(gipr)에 대한 결합 단백질을 이용하여 대사 장애를 치료하거나 또는 개선시키는 방법
|
|
CA3066251A1
(en)
|
2017-06-21 |
2018-12-27 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
|
|
SG11202000625PA
(en)
|
2017-07-27 |
2020-02-27 |
Adocia |
Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor
|
|
FR3082426A1
(fr)
|
2018-06-14 |
2019-12-20 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
|
|
TWI847306B
(zh)
|
2017-08-24 |
2024-07-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Ｇｌｐ-１組成物及其用途
|
|
CN107365375B
(zh)
*
|
2017-08-25 |
2019-03-01 |
莎穆(上海)生物科技有限公司 |
一种对glp-1受体具有高亲和性的多肽化合物及其制备方法和应用
|
|
FR3083700B1
(fr)
|
2018-07-13 |
2021-03-12 |
Adocia |
Formulation thermostable d'insuline humaine a21g
|
|
WO2020185533A1
(en)
|
2019-03-08 |
2020-09-17 |
Amgen Inc. |
Growth differentiation factor 15 combination therapy
|
|
EP3858373A1
(en)
|
2020-01-31 |
2021-08-04 |
Adocia |
Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
|
|
PE20230819A1
(es)
|
2020-02-18 |
2023-05-19 |
Novo Nordisk As |
Composiciones y usos de glp-1
|
|
EP3915572A1
(en)
|
2020-05-29 |
2021-12-01 |
Adocia |
Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
|
|
EP3915571A1
(en)
|
2020-05-29 |
2021-12-01 |
Adocia |
Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
|
|
EP4129324A1
(en)
|
2021-08-02 |
2023-02-08 |
Adocia |
Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
|
|
WO2024123812A1
(en)
|
2022-12-05 |
2024-06-13 |
Shattuck Labs, Inc. |
Fusion proteins for the treatment of cardiometabolic diseases
|
|
GB202308304D0
(en)
|
2023-06-02 |
2023-07-19 |
Univ Ulster |
A fusion peptide for activation of the apj and/or glp-1 receptors
|